Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis

Virology Journal

Hong Ren¹  Peng Hu¹  Dazhi Zhang¹  Huaidong Hu¹  Fang Wei²  Xiwei Wang¹  Fen Liu² 

[1] Department of Infectious Diseases, Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China;Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

关键词: Naive;    Lamivudine;    Entecavir;    De novo;    Combination;    Adefovir dipivoxil;   

Others  :  806471
DOI  :  10.1186/1743-422X-11-59

 received in 2013-11-27, accepted in 2014-03-20,  发布年份 2014

【 摘 要 】

Background

Currently, there is no consensus on the efficacy and resistance of de novo combination therapy versus monotherapy for treatment naive patients of chronic hepatitis B (CHB).

Objectives

The aim of this study was to evaluate the effectiveness and resistance of de novo combination of lamivudine (LAM) and adefovir dipivoxil (ADV) compared with entecavir (ETV) monotherapy for nucleos(t)ide–naive patients with CHB.

Study design

Publications on the effectiveness and resistance of LAM plus ADV versus ETV monotherapy for nucleos(t)ide-naive patients with CHB were identified by a search of PubMed, Embase, the Cochrane Library, Web of science, OVID, and CBM (Chinese Biological Medical Literature) until May 1, 2013. Biochemical response, hepatitis B e antigen seroconversion, and viroligic response were extracted and combined to obtain an integrated result. Viral resistance and safety were reviewed.

Results

Five eligible studies (328 patients in total) were included in the analysis. LAM plus ADV combination therapy produced more rapid HBV DNA reduction rate at 12 weeks than that of ETV monotherapy. At 48 weeks, the combination group had superior viroligic response rates compared with ETV group (90.0% vs. 78.9%, P=0.01). The difference in the ALT normalization and HBeAg seroconversion rates was not found. At week 96, LAM + ADV was more effective than ETV in ALT normalization [RR = 1. 11, 95% CI (1.02, 1.21), P =0.01] and HBeAg seroconversion [RR = 2.00, 95% CI (1.26, 3.18, P=0.003)], and no significant difference was found in the virologic response (P =0.23). No viral resistance occurred in combination therapy and six patients in ETV group were experienced with viral breakthrough. Both groups were well tolerated.

Conclusion

The de novo LAM plus ADV combination therapy for treatment-naïve patients with CHB was greater than ETV monotherapy in both biochemical response and HBeAg seroconversion rate up to 96 weeks. The rate of emergence of viral resistance in the combination group was less than that in the ETV monotherapy.

【 授权许可】

   
2014 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Dienstag JL: Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2009, 49:S112-S121.
• [2]Fung J, Lai CL, Seto WK, Yuen MF: Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 2011, 66:2715-2725.
• [3]Ghany MG, Doo EC: Antiviral resistance and hepatitis B therapy. Hepatology 2009, 49:S174-S184.
• [4]Qiu YW, Jiang XH, Huang LH, Hu TH, Ding H, Jiang YM, Dai YX, Zhou M: A study on the treatment of chronic hepatitis B with YMDD mutation. Zhonghua Gan Zang Bing Za Zhi 2009, 17:171-174.
• [5]Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L: Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003, 36:687-696.
• [6]Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD: A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis 2009, 10:131-137.
• [7]Zoulim F, Locarnini S: Management of treatment failure in chronic hepatitis B. J Hepatol 2012, 56:S112-S122.
• [8]Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M: Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
• [9]Shepherd J, Gospodarevskaya E, Frampton G, Cooper K: Entecavir for the treatment of chronic hepatitis B infection. Health Technol Assess 2009, 13(Suppl 3):31-36.
• [10]Zhang Q, Cheng ML, Liu Q, Mu M, Zhang YY, Liu BY: Efficacy of entecavir in nucleoside-naive patients with hepatitis B e antigen-positive chronic hepatitis B. World Chin J Digestol 2009, 17:2846-2849.
• [11]Tujios SR, Lee WM: Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 2013, 29:250-256.
• [12]Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E: A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008, 48:1460-1466.
• [13]Patterson SJ, Angus PW: Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009, 14:225-230.
• [14]Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI: Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010, 25:1374-1380.
• [15]Chen EQ, Wang LC, Lei J, Xu L, Tang H: Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J 2009, 6:163. BioMed Central Full Text
• [16]Ijaz S, Arnold C, Dervisevic S, Mechurova J, Tatman N, Tedder RS, Naoumov NV: Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol 2008, 80:1160-1170.
• [17]Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ: Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007, 45:307-313.
• [18]Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol 2010, 53:449-454.
• [19]Kim SS, Cho SW, Kim SO, Hong SP, Cheong JY: Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy. J Med Virol 2013, 85:55-64.
• [20]Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, Brosgart CL, Woessner MA, Scott SA, Gray DF, Gardner SD: Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008, 48:728-735.
• [21]Wang LC, Chen EQ, Cao J, Liu L, Zheng L, Li DJ, Xu L, Lei XZ, Liu C, Tang H: De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol Int 2011, 5:671-676.
• [22]Yu JH, Shi JP, Wu J, Li XO, Guo JC, Xun YH, Zhao C, Jin J, Xu AF, Lou GQ: Efficacy and safety of lamivudine plus adefovir combination therapy and entecavir monotherapy for chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2011, 19:88-92.
• [23]Jayakumar R, Joshi YK, Singh S: Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J Lab Physicians 2012, 4:10-16.
• [24]Zhang JC: De novo combination therapy with lamivudine and adefovir dipivoxii versus entecavir monotherapy for naive chronic hepatitis B patients with high viral loads. Zhong Hua Lin Chuang Gan Ran Bing Xue Za Zhi 2012, 3:142-144.
• [25]Wei W, Huang ZM: Effect of entecavir and lamivudine combined with adefovir in treatment of e antigen-positive chronic hepatitis B. Zhong Hua Yi Yuan Gan Ran Bing Xue Za Zhi 2012, 22:4335-4336.
• [26]Wolters LMM, Niesters HGM, de Man RA: Nucleoside analogues for chronic hepatitis B. Eur J Gastroen Hepat 2001, 13:1499-1506.
• [27]Yu MM, Gu XJ, Xia Y, Wang GJ, Kan NY, Wu KH: Relationship between the expression of HBV DNA, HBV cccDNA in human ovary tissues and the HBV intrauterine infection. Zhonghua Liu Xing Bing Xue Za Zhi 2013, 34:178-182.
• [28]Kim do Y, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH: Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Gut Liver 2013, 7:329-334.
• [29]Neumann-Fraune M, Beggel B, Pfister H, Kaiser R, Verheyen J: High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates. J Med Virol 2013, 85:775-779.
• [30]Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH: Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int 2013, 33:244-254.
• [31]Sinn DH, Lee H, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH: Viroligic response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011, 17:3526-3530.
• [32]Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F: Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48:747-755.
• [33]Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ: Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004, 48:3498-3507.
• [34]Nagasaki F, Niitsuma H, Ueno Y, Inoue J, Kogure T, Fukushima K, Shimosegawa T: The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus. Tohoku J Exp Med 2007, 213:181-186.
• [35]Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785-791.
• [36]Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA: Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007, 147:745-754.
• [37]Das J: Hepatitis B management. Clin Pharm 2010, 2:17-21.
• [38]Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503-1514.
• [39]Lu HY, Zhuang LW, Yu YY, Si CW: Viroligic response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 2010, 17:59-65.
• [40]He Z, Wang J, Liu K, Huang H, Du Y, Lin Z, Cai M, Feng X: Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic hepatitis B. Clin Res Hepatol Gastroenterol 2012, 36:592-597.
• [41]Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, Lai ST, Wong WM, Lai LS, Poon RT, Lo CM, Fan ST, Lau GK: Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007, 46:690-698.
• [42]Wu B, Shen J, Cheng H: Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. BMC Health Serv Res 2012, 12:385. BioMed Central Full Text
• [43]Thornton A, Lee P: Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000, 53:207-216.